Pharvaris N.V.

Biotechnology • Healthcare • Zug, Switzerland • PHVS (NMS)

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Pharvaris (NASDAQ:PHVS) Shares Up 3.8% - Should You Buy? - MarketBeat

MarketBeat • Dec 31

Pharvaris (Nasdaq: PHVS) posts positive RAPIDe-3 data, targets 1H 2026 NDA filing - Stock Titan

Stock Titan • Dec 3

Pharvaris stock surges after positive HAE treatment study results - Investing.com

Investing.com • Dec 3

Biotechs Duke It Out In A Genetic Disease — And Both Surge - Investor's Business Daily

Investor's Business Daily • Dec 3

Why Pharvaris (PHVS) Is Up 13.3% After RAPIDe-3 Success And 2026 Deucrictibant Filing Plans - Sahm

Sahm • Dec 23

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Pharvaris N.V. had layoffs?

No layoff events have been recorded for Pharvaris N.V. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Pharvaris N.V. have?

Pharvaris N.V. has approximately 118 employees.

What industry is Pharvaris N.V. in?

Pharvaris N.V. operates in the Biotechnology industry, within the Healthcare sector.

Is Pharvaris N.V. a publicly traded company?

Yes, Pharvaris N.V. is publicly traded under the ticker symbol PHVS on the NMS. The company has a market capitalization of approximately $1.68 billion.

Where is Pharvaris N.V. headquartered?

Pharvaris N.V. is headquartered in Zug, Switzerland.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.